Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study.

ABSTRACT:

Purpose

To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab.

Design

Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network.

Subjects

Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion).

Methods

The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from eac

SUBMITTER: Cai CX 

PROVIDER: S-EPMC11298306 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature